BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Spizzo G, Puccini A, Xiu J, Goldberg RM, Grothey A, Shields AF, Arora SP, Khushman M, Salem ME, Battaglin F, Baca Y, El-Deiry WS, Philip PA, Nassem M, Hall M, Marshall JL, Kocher F, Amann A, Wolf D, Korn WM, Lenz HJ, Seeber A. Molecular profile of BRCA-mutated biliary tract cancers. ESMO Open 2020;5:e000682. [PMID: 32576609 DOI: 10.1136/esmoopen-2020-000682] [Cited by in Crossref: 22] [Cited by in F6Publishing: 35] [Article Influence: 22.0] [Reference Citation Analysis]
Number Citing Articles
1 Yuan ZG, Zeng TM, Tao CJ. Current and emerging immunotherapeutic approaches for biliary tract cancers. Hepatobiliary Pancreat Dis Int 2022:S1499-3872(22)00201-6. [PMID: 36115807 DOI: 10.1016/j.hbpd.2022.08.015] [Reference Citation Analysis]
2 Zhou T, Mahn R, Möhring C, Sadeghlar F, Meyer C, Toma M, Kreppel B, Essler M, Glowka T, Matthaei H, Kalff JC, Strassburg CP, Gonzalez-carmona MA. Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate. Front Oncol 2022;12:933943. [DOI: 10.3389/fonc.2022.933943] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Carotenuto M, Sacco A, Forgione L, Normanno N. Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy. Exploration of Targeted Anti-tumor Therapy. [DOI: 10.37349/etat.2022.00079] [Reference Citation Analysis]
4 Azzollini J, Vingiani A, Agnelli L, Tamborini E, Perrone F, Conca E, Capone I, Busico A, Peissel B, Rosina E, Ducceschi M, Mantiero M, Lopez S, Raspagliesi F, Niger M, Duca M, Damian S, Proto C, de Braud F, Pruneri G, Manoukian S. Management of BRCA Tumour Testing in an Integrated Molecular Tumour Board Multidisciplinary Model. Front Oncol 2022;12:857515. [PMID: 35463374 DOI: 10.3389/fonc.2022.857515] [Reference Citation Analysis]
5 Gönül Geyik Ö, Anichini G, Ulukaya E, Marra F, Raggi C. DNA Damage Response Inhibitors in Cholangiocarcinoma: Current Progress and Perspectives. Cells 2022;11:1463. [DOI: 10.3390/cells11091463] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
6 Giorgione R, Risaliti M, Bartolini I, Rossi G, Pillozzi S, Muiesan P, Taddei A, Antonuzzo L. The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers. Immunotherapy 2022. [PMID: 35382560 DOI: 10.2217/imt-2021-0257] [Reference Citation Analysis]
7 Kuwatani M, Kawakubo K, Sakamoto N. Promising Genomic Testing for Biliary Tract Cancer Using Endoscopic Ultrasound-Guided Fine-Needle Aspiration/Biopsy Specimens. Diagnostics 2022;12:900. [DOI: 10.3390/diagnostics12040900] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wang S, Tong Y, Zong H, Xu X, Crabbe MJC, Wang Y, Zhang X. Multi-Level Analysis and Identification of Tumor Mutational Burden Genes across Cancer Types. Genes 2022;13:365. [DOI: 10.3390/genes13020365] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Canale M, Monti M, Rapposelli IG, Ulivi P, Sullo FG, Bartolini G, Tiberi E, Frassineti GL. Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer. Cancers (Basel) 2021;13:5671. [PMID: 34830826 DOI: 10.3390/cancers13225671] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
10 Rimini M, Puzzoni M, Pedica F, Silvestris N, Fornaro L, Aprile G, Loi E, Brunetti O, Vivaldi C, Simionato F, Zavattari P, Scartozzi M, Burgio V, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Cholangiocarcinoma: new perspectives for new horizons. Expert Rev Gastroenterol Hepatol 2021;:1-17. [PMID: 34669536 DOI: 10.1080/17474124.2021.1991313] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Zimmer K, Kocher F, Puccini A, Seeber A. Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives. Front Oncol 2021;11:662055. [PMID: 34707985 DOI: 10.3389/fonc.2021.662055] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
12 Kuipers H, de Bitter TJJ, de Boer MT, van der Post RS, Nijkamp MW, de Reuver PR, Fehrmann RSN, Hoogwater FJH. Gallbladder Cancer: Current Insights in Genetic Alterations and Their Possible Therapeutic Implications. Cancers (Basel) 2021;13:5257. [PMID: 34771420 DOI: 10.3390/cancers13215257] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
13 Persano M, Puzzoni M, Ziranu P, Pusceddu V, Lai E, Pretta A, Donisi C, Pinna G, Spanu D, Cimbro E, Parrino A, Liscia N, Mariani S, Dubois M, Migliari M, Scartozzi M. Molecular-driven treatment for biliary tract cancer: the promising turning point. Expert Rev Anticancer Ther 2021;21:1253-64. [PMID: 34551663 DOI: 10.1080/14737140.2021.1982699] [Reference Citation Analysis]
14 Zhang R, Puzzoni M, Mariani S, Zheng Y, Liscia N, Guo Y, Donisi C, Liu Y, Impera V, Fang W, Scartozzi M. Emerging treatment evolutions and integrated molecular characteristics of biliary tract cancers. Cancer Sci 2021. [PMID: 34534382 DOI: 10.1111/cas.15139] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Zeng FL, Chen JF. Application of Immune Checkpoint Inhibitors in the Treatment of Cholangiocarcinoma. Technol Cancer Res Treat 2021;20:15330338211039952. [PMID: 34528830 DOI: 10.1177/15330338211039952] [Reference Citation Analysis]
16 Su YL, Ng CT, Jan YH, Hsieh YL, Wu CL, Tan KT. Remarkable Response to Olaparib in a Patient with Combined Hepatocellular-Cholangiocarcinoma Harboring a Biallelic BRCA2 Mutation. Onco Targets Ther 2021;14:3895-901. [PMID: 34234458 DOI: 10.2147/OTT.S317514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Suda R, Sakai N, Matsushita K, Ishige T, Kawasaki Y, Shiko Y, Furukawa K, Mishima T, Nakadai E, Ohtsuka M. Prediction of mismatch repair deficient biliary tract cancer: Role of morphological features and host immune response detected by routine hematoxylin-eosin staining. J Hepatobiliary Pancreat Sci 2021;28:680-91. [PMID: 33998775 DOI: 10.1002/jhbp.988] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Yao W, Gong W. Immunotherapy in cholangiocarcinoma: From concept to clinical trials. Surgery in Practice and Science 2021;5:100028. [DOI: 10.1016/j.sipas.2021.100028] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
19 Yu J, Zhang X, Huang Q, Tan S, Xiong X, Gou H. Rare DNA Mismatch Repair-Related Protein Loss in Patients with Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma and Their Response to Immunotherapy. Cancer Manag Res 2021;13:4283-90. [PMID: 34113169 DOI: 10.2147/CMAR.S304281] [Reference Citation Analysis]
20 Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice? Cancers (Basel) 2021;13:2708. [PMID: 34070929 DOI: 10.3390/cancers13112708] [Cited by in Crossref: 1] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
21 Li X, Gao L, Qiu M, Cao D. Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation. Onco Targets Ther 2021;14:2815-9. [PMID: 33911878 DOI: 10.2147/OTT.S303594] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Fiste O, Ntanasis-Stathopoulos I, Gavriatopoulou M, Liontos M, Koutsoukos K, Dimopoulos MA, Zagouri F. The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma. Vaccines (Basel) 2021;9:422. [PMID: 33922362 DOI: 10.3390/vaccines9050422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ricci AD, Rizzo A, Brandi G. Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look. Cancer Control 2020;27:1073274820948047. [PMID: 32806956 DOI: 10.1177/1073274820948047] [Cited by in Crossref: 18] [Cited by in F6Publishing: 34] [Article Influence: 18.0] [Reference Citation Analysis]
24 Mehta R, Wood AC, Yu J, Kim R. Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies. Expert Opin Investig Drugs 2021;30:451-61. [PMID: 33660569 DOI: 10.1080/13543784.2021.1898586] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
25 Rizzo A, Ricci AD, Brandi G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin Investig Drugs 2021;30:343-50. [PMID: 33645367 DOI: 10.1080/13543784.2021.1897102] [Cited by in Crossref: 7] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
26 Yang W, Sun Y. Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview. Onco Targets Ther 2021;14:1341-66. [PMID: 33658799 DOI: 10.2147/OTT.S297643] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
27 Rizzo A, Brandi G. First-line Chemotherapy in Advanced Biliary Tract Cancer Ten Years After the ABC-02 Trial: "And Yet It Moves!". Cancer Treat Res Commun 2021;27:100335. [PMID: 33592561 DOI: 10.1016/j.ctarc.2021.100335] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
28 Rizzo A, Ricci AD, Brandi G. PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer. Cancers (Basel) 2021;13:558. [PMID: 33535621 DOI: 10.3390/cancers13030558] [Cited by in Crossref: 25] [Cited by in F6Publishing: 66] [Article Influence: 25.0] [Reference Citation Analysis]
29 Chiang NJ, Chen LT, Shan YS, Yeh CN, Chen MH. Development of Possible Next Line of Systemic Therapies for Gemcitabine-Resistant Biliary Tract Cancers: A Perspective from Clinical Trials. Biomolecules 2021;11:97. [PMID: 33451059 DOI: 10.3390/biom11010097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Ricci AD, Rizzo A, Brandi G. The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box? ESMO Open 2020;5:e001042. [PMID: 32994319 DOI: 10.1136/esmoopen-2020-001042] [Cited by in Crossref: 22] [Cited by in F6Publishing: 29] [Article Influence: 22.0] [Reference Citation Analysis]
31 Rizzo A, Ricci AD, Brandi G. Recent advances of immunotherapy for biliary tract cancer. Expert Rev Gastroenterol Hepatol 2021;15:527-36. [PMID: 33215952 DOI: 10.1080/17474124.2021.1853527] [Cited by in Crossref: 13] [Cited by in F6Publishing: 55] [Article Influence: 13.0] [Reference Citation Analysis]
32 Di Federico A, Rizzo A, Ricci AD, Frega G, Palloni A, Tavolari S, Brandi G. Nivolumab: an investigational agent for the treatment of biliary tract cancer. Expert Opin Investig Drugs 2021;30:325-32. [PMID: 33307866 DOI: 10.1080/13543784.2021.1863946] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
33 Rizzo A, Tavolari S, Ricci AD, Frega G, Palloni A, Relli V, Salati M, Fenocchio E, Massa A, Aglietta M, Brandi G. Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures. Cancers (Basel) 2020;12:E3256. [PMID: 33158162 DOI: 10.3390/cancers12113256] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
34 Yang Y, Deng X, Li Q, Wang F, Miao L, Jiang Q. Emerging roles of long noncoding RNAs in cholangiocarcinoma: Advances and challenges. Cancer Commun (Lond) 2020;40:655-80. [PMID: 33142045 DOI: 10.1002/cac2.12109] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
35 Song X, Hu Y, Li Y, Shao R, Liu F, Liu Y. Overview of current targeted therapy in gallbladder cancer. Signal Transduct Target Ther 2020;5:230. [PMID: 33028805 DOI: 10.1038/s41392-020-00324-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
36 Ricci AD, Rizzo A, Bonucci C, Tober N, Palloni A, Mollica V, Maggio I, Deserti M, Tavolari S, Brandi G. PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block? Medicines (Basel) 2020;7:E54. [PMID: 32878011 DOI: 10.3390/medicines7090054] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]